TY - JOUR
T1 - New landscapes and horizons in hepatocellular carcinoma therapy
AU - Emma, Maria Rita
AU - Soresi, Maurizio
AU - Giannitrapani, Lydia
AU - Belmonte, Beatrice
AU - Montalto, Giuseppe
AU - Cervello, Melchiorre
AU - Augello, Giuseppa
AU - Emma, Maria R.
AU - Giannitrapani, Lydia
AU - Cusimano, Antonella
AU - Akula, Shaw M.
AU - Steelman, Linda S.
AU - Mccubrey, James A.
AU - Montalto, Giuseppe
AU - Abrams, Stephen L.
PY - 2020
Y1 - 2020
N2 - Hepatocellular carcinoma (HCC), is the sixth most frequent form of cancer and leads to the fourth highest number of deaths each year. HCC results from a combination of environmental factors and aging as there are driver mutations at oncogenes which occur during aging. Most of HCCs are diagnosed at advanced stage preventing curative therapies. Treatment in advanced stage is a challenging and pressing problem, and novel and well-tolerated therapies are urgently needed. We will discuss further advances beyond sorafenib that target additional signaling pathways and immune checkpoint proteins. The scenario of possible systemic therapies for patients with advanced HCC has changed dramatically in recent years. Personalized genomics and various other omics approaches may identify actionable biochemical targets, which are activated in individual patients, which may enhance therapeutic outcomes. Further studies are needed to identify predictive biomarkers and aberrantly activated signaling pathways capable of guiding the clinician in choosing the most appropriate therapy for the individual patient.
AB - Hepatocellular carcinoma (HCC), is the sixth most frequent form of cancer and leads to the fourth highest number of deaths each year. HCC results from a combination of environmental factors and aging as there are driver mutations at oncogenes which occur during aging. Most of HCCs are diagnosed at advanced stage preventing curative therapies. Treatment in advanced stage is a challenging and pressing problem, and novel and well-tolerated therapies are urgently needed. We will discuss further advances beyond sorafenib that target additional signaling pathways and immune checkpoint proteins. The scenario of possible systemic therapies for patients with advanced HCC has changed dramatically in recent years. Personalized genomics and various other omics approaches may identify actionable biochemical targets, which are activated in individual patients, which may enhance therapeutic outcomes. Further studies are needed to identify predictive biomarkers and aberrantly activated signaling pathways capable of guiding the clinician in choosing the most appropriate therapy for the individual patient.
UR - http://hdl.handle.net/10447/408600
M3 - Article
SN - 1945-4589
VL - 12
SP - 3053
EP - 3094
JO - Aging
JF - Aging
ER -